Pharma Two B (Israel), a pre-clinical stage pharmaceutical company focused on developing Fixed-Dose-combinations of approved drugs for Parkinson’s disease and Cancer, closed a $8 million Series B financing. Participants include JK&B Capital and Crossroad. ___________ Collective IP the Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem

NeuroPhage Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on small molecules for protein aggregation diseases such as Alzheimer’ and Parkinson’s disease, closed a $9M Series B financing, bringing the total round to $21.4M. Participants include Merieux Developpement and Shire.

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

MedGenesis Therapeutix (Canada) a clinical-stage biopharmaceutical company focused on glial cell-derived neurotrophic factor protein for CNS diseases such as Parkinson’s disease, epilepsy and sensorineural hearing loss, closed a $5M Series C financing. Participants were not disclosed.

Neuraltus Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on small molecule drugs for the neurodegenerative diseases such as ALS multiple sclerosis, Parkinson’s, Alzheimer’s, Fabry’s and Gaucher’s diseases, closed a $9.6M Series B financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Civitas Therapeutics (Chelsea, MA) a preclinical-stage dry powder pulmonary delivery platform and device combination company focused on for Parkinson’s disease, closed a $20M Series A financing. Participants include Longitude Capital and Canaan Partners.

Mind-NRD (Switzerland) a development-stage biopharmaceutical company focused on a neurotrophic factor for the treatment of Parkinson’s, Alzheimer’s and schizophrenia, closed a $2M Series A financing. Participants include Index Ventures.

Ceregene (San Diego, CA) a clinical-stage biopharmaceutical company focused adeno-associated virus vector-based gene therapy for Parkinson’s and Alzheimer’s disease, closed a $11.5M Series D financing. Participants include Hamilton BioVentures, Alta Partners, MPM Capital and Investor Growth Capital.

iPierian (San Francisco, CA) a development-stage induced pluripotent stem cell (iPSC) drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $6M Series B financing, bring the round total to $28M. Participants include SR One, Biogen Idec, Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins [...]

iPerian (San Francisco, CA) a development-stage induced pluripotent stem cell drug discovery company focused upon neurodegenerative disease including ALS and Parkinson’s, closed a $22M Series B financing. Participants include Google Ventures, Mitsubishi UFJ Capital, ATEL Ventures, MPM Capital, Highland Capital Partners and Kleiner Perkins Caufield & Byers.

Archimedes Pharma (United Kingdom) a commercial-stage specialty oncology company focused on pain and critical care, closed a $99M Series C financing. Participants include Novo Growth Equity and Warburg Pincus.

Adamas Pharmaceuticals (Emeryville, CA) a development-stage small molecule company focused on neurological (Parkinson’s and dementia) and infectious (influenza) diseases, closed a $40M Series D financing. Participants include Aeris Capital, DAG Ventures, Mohr Davidow Ventures and Northgate Capital.

Avid Radiopharmaceuticals (Philadelphia, PA) a development-stage company focused on molecular imaging compounds for diagnostic and detection use in Alzheimer’s, dementia, Parkinson’s and diabetes, closed a $24.5M Series D financing. Participants include Alta Partners, AllianceBernstein, Safeguard Scientifics, Pfizer Venture Investments, Lilly Ventures, RK Ventures Group and BioAdvance.